GT201500039A - Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad de reflujo - Google Patents
Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad de reflujoInfo
- Publication number
- GT201500039A GT201500039A GT201500039A GT201500039A GT201500039A GT 201500039 A GT201500039 A GT 201500039A GT 201500039 A GT201500039 A GT 201500039A GT 201500039 A GT201500039 A GT 201500039A GT 201500039 A GT201500039 A GT 201500039A
- Authority
- GT
- Guatemala
- Prior art keywords
- disease
- parkinson
- fragile
- syndrome
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS DE DIAZEPINONA, A SU PREPARACIÓN, A SU USO COMO MEDICAMENTOS, Y A LOS MEDICAMENTOS QUE LOS COMPRENDEN. ESTOS DERIVADOS SON DE UTILIDAD EN PATOLOGÍAS TALES COMO EL MAL DE PARKINSON, SÍNDROME X FRÁGIL, ENFERMEDAD DE REFLUJO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1215033.0A GB201215033D0 (en) | 2012-08-23 | 2012-08-23 | Diazepinone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201500039A true GT201500039A (es) | 2018-11-27 |
Family
ID=47045285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201500039A GT201500039A (es) | 2012-08-23 | 2015-02-23 | Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad de reflujo |
Country Status (44)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201215033D0 (en) * | 2012-08-23 | 2012-10-10 | Novartis Ag | Diazepinone derivatives |
| US11878001B2 (en) | 2017-07-31 | 2024-01-23 | Novartis Ag | Use of mavoglurant in the reduction of ***e use or in preventing relapse into ***e use |
| JP2022518788A (ja) * | 2019-01-29 | 2022-03-16 | ノバルティス アーゲー | オピオイド鎮痛耐性を治療するためのｍＧｌｕＲ５アンタゴニストの使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3853851A (en) * | 1972-01-26 | 1974-12-10 | Ciba Geigy Corp | Diazepinoisoquinolines |
| GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
| CN100457731C (zh) * | 2003-03-26 | 2009-02-04 | 麦克公司 | 代谢型谷氨酸受体的苯甲酰胺调节剂 |
| GB0413605D0 (en) * | 2004-06-17 | 2004-07-21 | Addex Pharmaceuticals Sa | Novel compounds |
| TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
| CU20090172A6 (es) | 2009-10-09 | 2011-10-05 | Facultad De Quimica Universidad De La Habana | Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular |
| US8772301B2 (en) * | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| US9453021B2 (en) | 2011-05-10 | 2016-09-27 | Kyowa Hakko Kirin Co., Ltd. | Pyrimidodiazepinone compound |
| GB201215033D0 (en) * | 2012-08-23 | 2012-10-10 | Novartis Ag | Diazepinone derivatives |
-
2012
- 2012-08-23 GB GBGB1215033.0A patent/GB201215033D0/en not_active Ceased
-
2013
- 2013-08-21 CN CN201380042195.XA patent/CN104520298B/zh active Active
- 2013-08-21 JP JP2015527996A patent/JP6169699B2/ja not_active Expired - Fee Related
- 2013-08-21 PE PE2015000245A patent/PE20150401A1/es active IP Right Grant
- 2013-08-21 MX MX2015002367A patent/MX365253B/es active IP Right Grant
- 2013-08-21 AP AP2014008140A patent/AP2014008140A0/xx unknown
- 2013-08-21 CA CA2878564A patent/CA2878564C/en active Active
- 2013-08-21 SG SG11201500068QA patent/SG11201500068QA/en unknown
- 2013-08-21 LT LTEP13783671.4T patent/LT2888259T/lt unknown
- 2013-08-21 EA EA201590415A patent/EA029493B1/ru not_active IP Right Cessation
- 2013-08-21 HU HUE13783671A patent/HUE037971T2/hu unknown
- 2013-08-21 PL PL13783671T patent/PL2888259T3/pl unknown
- 2013-08-21 EP EP13783671.4A patent/EP2888259B1/en active Active
- 2013-08-21 MA MA37849A patent/MA37849A1/fr unknown
- 2013-08-21 RS RS20180581A patent/RS57231B1/sr unknown
- 2013-08-21 SI SI201331027T patent/SI2888259T1/en unknown
- 2013-08-21 MY MYPI2014003502A patent/MY170103A/en unknown
- 2013-08-21 WO PCT/IB2013/056782 patent/WO2014030128A1/en active Application Filing
- 2013-08-21 DK DK13783671.4T patent/DK2888259T3/en active
- 2013-08-21 KR KR1020157003903A patent/KR102104149B1/ko active IP Right Grant
- 2013-08-21 AU AU2013307239A patent/AU2013307239B2/en not_active Ceased
- 2013-08-21 UA UAA201413654A patent/UA114326C2/uk unknown
- 2013-08-21 PT PT137836714T patent/PT2888259T/pt unknown
- 2013-08-21 ES ES13783671.4T patent/ES2672737T3/es active Active
- 2013-08-21 NO NO13783671A patent/NO2888259T3/no unknown
- 2013-08-21 NZ NZ703628A patent/NZ703628A/en not_active IP Right Cessation
- 2013-08-21 TR TR2018/07174T patent/TR201807174T4/tr unknown
- 2013-08-21 SG SG10201701333WA patent/SG10201701333WA/en unknown
- 2013-08-21 BR BR112015003281A patent/BR112015003281A8/pt active Search and Examination
- 2013-08-22 TW TW102130096A patent/TWI616444B/zh not_active IP Right Cessation
- 2013-08-22 US US13/973,454 patent/US8853203B2/en active Active
- 2013-08-22 JO JOP/2013/0250A patent/JOP20130250B1/ar active
- 2013-08-22 UY UY0001034986A patent/UY34986A/es unknown
- 2013-08-23 AR ARP130102989A patent/AR092212A1/es not_active Application Discontinuation
-
2014
- 2014-08-19 US US14/462,813 patent/US9284331B2/en active Active
- 2014-12-18 ZA ZA2014/09345A patent/ZA201409345B/en unknown
- 2014-12-19 TN TN2014000528A patent/TN2014000528A1/fr unknown
-
2015
- 2015-02-02 IL IL237062A patent/IL237062A/en active IP Right Grant
- 2015-02-20 PH PH12015500373A patent/PH12015500373B1/en unknown
- 2015-02-20 CL CL2015000416A patent/CL2015000416A1/es unknown
- 2015-02-23 CU CUP2015000016A patent/CU20150016A7/es unknown
- 2015-02-23 GT GT201500039A patent/GT201500039A/es unknown
- 2015-02-23 CR CR20150092A patent/CR20150092A/es unknown
- 2015-07-02 HK HK15106284.5A patent/HK1206008A1/xx not_active IP Right Cessation
-
2016
- 2016-02-12 US US15/042,924 patent/US9650377B2/en active Active
-
2017
- 2017-04-28 US US15/581,642 patent/US20170305903A1/en not_active Abandoned
- 2017-06-28 JP JP2017125822A patent/JP2017226661A/ja not_active Withdrawn
-
2018
- 2018-05-29 HR HRP20180850TT patent/HRP20180850T1/hr unknown
- 2018-06-07 CY CY181100599T patent/CY1120728T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017003404A1 (es) | Compuestos antibacterianos | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| ECSP16078782A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| CR20150326A (es) | Inhibidores de autotaxina | |
| CR20140576A (es) | Sintesis de compuestos heterociclicos | |
| CL2013002517A1 (es) | Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer. | |
| UY34566A (es) | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CR20140161A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| UY36075A (es) | Derivados de tubulisina | |
| UY31645A1 (es) | Nuevas imidazolidinas fenil-sustituidas, procedimiento para su preparación, medicamentos que conprenden dichos compuestos y su uso. | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| DOP2016000212A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| GT201500012A (es) | Derivados de carbamato/urea | |
| ECSP14002542A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
| CR20160133A (es) | Derivados de fenilalanina sustituidos | |
| CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| CO7160067A2 (es) | Formulaciones de agonistas del receptor de somatostatina | |
| GT201500039A (es) | Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad de reflujo | |
| CL2015000290A1 (es) | Compuestos derivados de ariletinilo. moduladores alostéricos del receptor de glutamato mglur5; proceso de obtencion; composicion farmaceuticas: y su uso en el tratamiento o prevencon de la esquizofenia, enfermedades cognitivas, sindrome de x fragil o autismo | |
| UY34752A (es) | Agentes para el control de la chinche del eucalipto |